2017
CMET-25. PROGRESSION-FREE SURVIVAL (PFS) AND SITE OF FIRST PROGRESSION IN HER2+ METASTATIC BREAST CANCER PATIENTS WITH OR WITHOUT BRAIN METASTASES: A POOLED ANALYSIS OF TUCATINIB PHASE I STUDIES
Hamilton E, Moulder S, Ferrario C, Conlin A, Krop I, Chamberlain M, Gray T, Borges V. CMET-25. PROGRESSION-FREE SURVIVAL (PFS) AND SITE OF FIRST PROGRESSION IN HER2+ METASTATIC BREAST CANCER PATIENTS WITH OR WITHOUT BRAIN METASTASES: A POOLED ANALYSIS OF TUCATINIB PHASE I STUDIES. Neuro-Oncology 2017, 19: vi44-vi44. PMCID: PMC5692086, DOI: 10.1093/neuonc/nox168.173.Peer-Reviewed Original ResearchProgression-free survivalBaseline brain metastasesMetastatic breast cancerBrain metastasesMedian progression-free survivalMetastatic breast cancer patientsPhase 1b studyProgressive brain metastasesStable brain metastasesSite of relapseIncidence of progressionSignificant neurologic morbidityUntreated brain metastasesBreast cancer patientsTyrosine kinase inhibitorsBM cohortHER2 therapyHER2CLIMB trialPrior HER2Neurologic morbidityDurable responsesFirst progressionSystemic metastasesCombination therapyPatient cohort
2010
Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.
LoRusso P, Krop I, Burris H, Vukelja S, Miller K, Zheng M, Chu Y, Lu M, Amler L, Rugo H. Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy. Journal Of Clinical Oncology 2010, 28: 1016-1016. DOI: 10.1200/jco.2010.28.15_suppl.1016.Peer-Reviewed Original Research